Company Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies.
The company was incorporated in 1987 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 1987 |
| IPO Date | Jan 22, 1992 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 18,000 |
| CEO | Daniel P. O'Day |
Contact Details
Address: 333 Lakeside Drive Foster City, California 94404 United States | |
| Phone | 650 574 3000 |
| Website | gilead.com |
Stock Details
| Ticker Symbol | GILD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000882095 |
| CUSIP Number | 375558103 |
| ISIN Number | US3755581036 |
| Employer ID | 94-3047598 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel P. O'Day | Chief Executive Officer |
| Andrew Dickinson | Chief Financial Officer |
| Jacquie Ross | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | 4 | Statement of changes in beneficial ownership of securities |
| Dec 19, 2024 | 4 | Statement of changes in beneficial ownership of securities |
| Dec 16, 2024 | 144 | Filing |
| Dec 13, 2024 | 8-K/A | [Amend] Current report |
| Nov 29, 2024 | 144 | Filing |
| Nov 27, 2024 | 144 | Filing |
| Nov 26, 2024 | 144 | Filing |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 424B5 | Filing |
| Nov 13, 2024 | FWP | Free Writing Prospectus |